Pharmaceutical Technology

SEPTEMBER 15, 2022

Regeneron’s windfall of $16.1bn in revenue for the year was largely due to its Covid-19 monoclonal antibody therapy, REGEN-COV; due to its ineffectiveness against the Omicron variant, however, its success is expected to be short-lived. Moderna’s Covid-19 vaccine, Spikevax, also contributed to the company’s $18.5bn in revenue for the year.

Vaccine 272

Vaccine Vaccination Sales Generic Drugs 272

Pharmaceutical Technology

DECEMBER 20, 2022

The growing competition from generic drugs presents challenges for the top 20 players placing pressure on drug prices. The FDA also awarded priority review for Eli Lilly’s donanemab, a monoclonal antibody for Alzheimer’s disease, in August 2022, and the company expects approval by February 2023. trillion in Q2 2022 to $3.14

Marketing 130

Marketing Vaccine Vaccination Sales 130

pharmaphorum

OCTOBER 28, 2021

Antibody therapies have also been developed for use in non-hospitalised patients, but these still have to be administered by infusion in a clinic. Merck is also testing its drug for prevention of COVID-19 in patients exposed to SARS-CoV-2, and analysts said that could increase sales projections if the results are positive.

Generic Drugs 98

Generic Drugs Sales Drugs Licensing 98

XTalks

JANUARY 20, 2025

Blockbuster products like Botox (botulinum toxin) and Restasis (cyclosporine) provided Actavis with high-margin, branded revenue streams that complemented its existing generic drug business. Key drivers of the acquisition included Allergans robust product portfolio, particularly in ophthalmology, neuroscience and aesthetics.

Marketing 104

Marketing Botox Life Science Pharma Companies 104

Camargo

MAY 10, 2021

the Center’s chief of medical oncology, In it, they laid out their analysis of accelerated approvals for 35 oncology indications for anti-programmed death ligand 1 antibodies and reported that for 10 of the 35 indications, the confirmatory trials failed to show a benefit. The meeting was prompted by a publication by Richard Pazdur, M.D.,

Development 185

Development Clinical Trials Clinical Trials Trials 185

XTalks

FEBRUARY 8, 2021

In order to fact-check some of these misconceptions, the US Food and Drug Administration (FDA) recently hosted a webinar on biosimilar and interchangeable biological products to help healthcare professionals understand more about these treatment options. Biosimilars are the “generic” drugs of the biopharma world.

Production 78

Production Insulin Branding Generic Drugs 78

XTalks

FEBRUARY 5, 2024

Why it did so well: Darzalex was the first human anti-CD38 monoclonal antibody approved by the FDA for multiple myeloma. Despite Bristol Myers Squibb’s Revlimid remaining the top-selling drug for multiple myeloma for several years now, Darzalex is not too far behind. The worldwide net trade sales of Darzalex were $2.26

FDA Approval 101

FDA Approval Drugs Sales Development 101